丁苯酞联合银杏叶提取物注射液对老年缺血性脑血管病患者的疗效分析

doi:10.3760/cma.j.issn.1007-1245.2024.03.011

摘要/Abstract

摘要：

目的　探讨丁苯酞联合银杏叶提取物注射液对老年缺血性脑血管病患者的疗效与安全性。方法　前瞻性研究，选取2021年3月至2023年1月西安高新医院神经内科诊治的90例老年缺血性脑血管病患者为研究对象，按诊治先后顺序分为对照组和观察组。观察组中男性25例，女性20例，年龄67～76（69.72±4.03）岁，在常规治疗的基础上采用丁苯酞联合银杏叶提取物注射液；对照组中男性22例，女性23例，年龄66～78（69.58±4.26）岁，在常规治疗的基础上服用丁苯酞。两组均接受2周治疗，记录并比较治疗后两组患者的血流动力学指标（全血低切黏度、全血高切黏度和血浆黏度）、脑血流指标（脑血管外周阻力和颈动脉舒张期末血流速度）、美国国立卫生研究院卒中量表（NIHSS）以及日常生活活动（ADL）评分，评估临床疗效及治疗期间不良反应发生情况。统计学方法采用χ²检验、t检验。结果　治疗后，观察组全血低切黏度、全血高切黏度和血浆黏度均低于对照组［（7.13±1.21）mPa·s比（8.26±1.46）mPa·s、（4.89±0.88）mPa·s比（5.78±1.04）mPa·s、（1.59±0.31）mPa·s比（1.86±0.34）mPa·s］，差异均有统计学意义（t=4.00、4.38、3.94，均P<0.05）。治疗后，观察组颈动脉舒张期末血流速度高于对照组，脑血管外周阻力低于对照组［（96.48±5.31）cm/s比（89.46±4.82）cm/s、（1.68±0.23）kPa·s/ml比（1.96±0.25）kPa·s/ml］，差异均有统计学意义（t=6.57、5.53，均P<0.05）。治疗后，观察组ADL评分高于对照组，NIHSS评分低于对照组［（69.74±5.19）分比（56.64±5.33）分、（5.12±1.13）分比（8.18±1.45）分］，差异均有统计学意义（t=11.81、11.17，均P<0.05）。观察组总有效率高于对照组［91.11%（41/45）比73.33%（33/45）］，差异有统计学意义（χ²=4.87，P<0.05）。治疗期间，观察组不良反应总发生率为6.67%（3/45），对照组为8.89%（4/45），差异无统计学意义（χ²=0.16，P>0.05）。结论　在老年患者缺血性脑血管病的治疗中，丁苯酞联合银杏叶提取物注射液表现出显著的临床效果，而且具备良好的安全性。

关键词:

脑缺血, 短暂性脑缺血发作, 丁苯酞, 银杏叶提取物, 缺血性脑血管病, 老年患者

Abstract:

Objective　To explore the efficacy and safety of dihydroergotoxine combined with ginkgo biloba extract injection for elderly patients with ischemic cerebrovascular disease. Methods　In this prospective study, 90 elderly patients with ischemic cerebrovascular disease treated at Department of Neurology, Xi'an Gaoxin Hospital from March 2021 to January 2023 were divided into a control group and an observation group according to the treatment order, with 45 cases in each group. There were 25 males and 20 females in the observation group; they were 67-76 (69.72±4.03) years old. There were 22 males and 23 females in the control group; they were 66-78 (69.58±4.26) years old. Both groups were routinely treated; in addition, the observation group were treated with dihydroergotoxine and ginkgo biloba extract injection, and the control group with dihydroergotoxine. Both groups were treated for 2 weeks. The hemodynamic and cerebral blood flow indicators (blood low shear viscosity, blood high shear viscosity, and plasma viscosity), brain blood flow indicators (cerebrovascular peripheral resistance and end diastolic blood flow velocity of carotid artery), and scores of National Institute of Health Stroke Scale (NIHSS) and Activities of Daily Living (ADL) after the treatment in both groups were recorded and compared. The clinical efficacies and incidences of adverse reactions were compared between the two groups. χ² and t tests were used. Results　After the treatment, the blood low shear viscosity, blood high shear viscosity, and plasma viscosity in the observation group were lower than those in the control group [(7.13±1.21) mPa·s vs. (8.26±1.46) mPa·s, (4.89±0.88) mPa·s vs. (5.78±1.04) mPa·s, and (1.59±0.31) mPa·s vs. (1.86±0.34) mPa·s], with statistical differences (t=4.00, 4.38, and 3.94; all P<0.05). The end diastolic blood flow velocity of carotid artery and cerebrovascular peripheral resistance in the observation group were better than those in the control group [(96.48±5.31)cm/s vs. (89.46±4.82) cm/s and (1.68±0.23) kPa·s/ml vs.(1.96±0.25) kPa·s/ml], with statistical differences (t=6.57 and 5.53; both P<0.05). After the treatment, the scores of ADL and NIHSS in the observation group were better than those in the control group [(69.74±5.19) vs. (56.64±5.33) and (5.12±1.13) vs. (8.18±1.45)], with statistical differences (t=11.81 and 11.17; both P<0.05). The total effective rate in the observation group was higher than that in the control group [91.11% (41/45) vs. 73.33% (33/45)], with a statistical difference (χ²=4.87; P<0.05). There was no statistical difference in the total incidence of adverse reactions during the treatment between the observation group and the control group [6.67% (3/45) vs. 8.89% (4/45); χ²=0.16; P>0.05]. Conclusion　In the treatment of elderly Patients with ischemic cerebrovascular disease, the combination of dihydroergotoxine and ginkgo biloba extract injection demonstrates significant clinical efficacy and good safety.

Key words:

Cerebral ischemia, Transient ischemic attack, Dihydroergotoxine, Ginkgo biloba extract, Ischemic cerebrovascular disease, Elderly patients

侯芳芳闫立萍刘晨阳.

丁苯酞联合银杏叶提取物注射液对老年缺血性脑血管病患者的疗效分析 [J]. 国际医药卫生导报, 2024, 30(3): 404-408.

Hou Fangfang, Yan Liping, Liu Chenyang.

Effect of dihydroergotoxine combined with ginkgo biloba extract injection for elderly patients with ischemic cerebrovascular disease [J]. International Medicine and Health Guidance News, 2024, 30(3): 404-408.

参考文献

[1] 贺国华,王振. 急性缺血性脑血管病血管内治疗进展[J]. 中国实用神经疾病杂志,2020,23(13):1193-1196,封3. DOI:10.12083/SYSJ.2020.13.271.
[2] 陈顺中. 慢性脑供血不足的中医治疗研究进展[J]. 实用老年医学,2023,37(2):124-127. DOI:10.3969/j.issn.1003- 9198. 2023.02.005.
[3] 王栋梁,杜艳芬,李新. 缺血性脑血管病治疗方法的研究现状[J]. 国际生物医学工程杂志,2022,45(4):362-367. DOI:10.3760/cma.j.cn121382-20220221-00414.
[4] 李睿雯,王丽华. 丁苯酞及其衍生物对缺血性脑血管病作用的研究[J]. 脑与神经疾病杂志,2020,28(7):447-450.
[5] 郭强蕊,张士奇,毛泽宇,等. 银杏叶提取物联合阿司匹林对经CT检测诊断为脑栓塞引起的老年缺血性脑血管病的临床疗效[J]. 中国老年学杂志,2023,43(14):3347-3350. DOI:10.3969/j.issn.1005-9202.2023.14.006.
[6] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682. DOI:10.3760/cma.j.issn.1006-7876.2018.09.004.
[7] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国脑血管病一级预防指南2019[J]. 中华神经科杂志,2019,52(9):684-709. DOI:10.3760/cma.j.issn. 1006?7876.2019.09.002.
[8] 刘萍萍,何学芳,张翼,等. SIVD继发认知障碍病人脑区灰质大小与认知功能的关系[J]. 中西医结合心脑血管病杂志,2022,20(11):2091-2094. DOI:10.12102/j.issn.1672- 1349. 2022.11.039.
[9] 张刚,胡德亮,周淑兰,等. NIHSS评分及D-二聚体早期预测缺血性脑卒中患者大血管闭塞的价值研究[J]. 中华急诊医学杂志,2023,32(2):236-240. DOI:10.3760/cma.j.issn. 1671-0282.2023.02.019.
[10] 张曼曼,梁志刚,詹焱. 新型口服抗凝药在非瓣膜性房颤合并脑血管病中的研究进展[J]. 国际医药卫生导报,2023,29(1):10-14. DOI:10.3760/cma.j.issn.1007-1245. 2023.01.003.
[11] 陈頔,朱愿超,李婷,等. 丁苯酞治疗缺血性脑血管病的快速卫生技术评估[J]. 中国医院用药评价与分析,2023,23(1):74-79. DOI:10.14009/j.issn.1672-2124.2023.01.016.
[12] 罗祥敏,雷芳,彭俊超,等. 基于网络药理学探究银杏叶提取物治疗脑血管痉挛的作用机制[J]. 化学试剂,2021,43(5):604-609. DOI:10.13822/j.cnki.hxsj.2021007929.
[13] 殷香,牛玉莲. 双重抗血小板联合丁苯酞治疗进展性脑梗死的预后因素分析[J]. 新疆医科大学学报,2023,46(6):763-767. DOI:10.3969/j.issn.1009-5551.2023.06.009.
[14] 秦保健,李琳,唐荣盛,等. 丁苯酞联合尤瑞克林对分水岭脑梗死急性期患者神经、血管内皮功能及血液流变学的影响[J]. 中国急救复苏与灾害医学杂志,2022,17(3):353-356. DOI:10.3969/j.issn.1673-6966.2022.03.019.
[15] 牟肖莉,王波,赵娟,等. 基于核因子NF-E2相关因子/血红素氧合酶-1信号通路研究丁苯酞对糖尿病脑小血管病大鼠的作用机制[J]. 中国新药杂志,2023,32(14):1467-1471. DOI:10.3969/j.issn.1003-3734.2023.14.013.
[16] 李建波,吴文燊,杜邦,等. 中重度缺氧缺血性脑病新生儿亚低温治疗诱导期血流动力学的变化探讨[J]. 中国当代儿科杂志,2021,23(2):133-137. DOI:10.7499/j.issn.1008- 8830. 2009083.
[17] Li C, Chai A, Gao Y, et al. Combination of tetrandrine and 3-n-butylphthalide protects against cerebral ischemia-reperfusion injury via ATF2/TLR4 pathway[J]. Immunopharmacol Immunotoxicol, 2021 ,43(6):749-757. DOI: 10.1080/08923973.2021.1979036.
[18] 李玲,江美芳,王丹丹,等. 银杏叶双黄酮化学成分及药理学研究进展[J]. 上海中医药大学学报,2022,36(2):101-108. DOI:10.16306/j.1008-861x.2022.02.016.
[19] Essawy AE, El-Sayed SA, Tousson E, et al. Anti-kindling effect of ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy[J]. Environ Sci Pollut Res Int, 2022,29(32):48573-48587. DOI: 10.1007/s11356-022-19251-6.
[20] Li Y, Xu C, Wang H, et al. Systems pharmacology reveals the multi-level synergetic mechanism of action of Ginkgo biloba L. leaves for cardiomyopathy treatment[J]. J Ethnopharmacol, 2021,264:113279. DOI: 10.1016/j.jep.2020.113279.
[21] Sharma G, Sharma N, Nguyen BT, et al. Protective potential of ginkgo biloba against an ADHD-like condition[J]. Curr Mol Pharmacol, 2021,14(2):200-209. DOI: 10.2174/1874467213666200424152454.
[22] 寇佳敏,杨宏昕,安明,等. 丁苯酞软胶囊治疗帕金森病临床疗效和安全性的Meta分析[J]. 中风与神经疾病杂志,2023,40(4):297-303. DOI:10.19845/j.cnki.zfysjjbzz.2023.0074.